Hypoxia–Reoxygenation Potentiates Zymosan Activated Plasma-Induced Endothelial Injury

The pathophysiology of ischemia–reperfusion injury and the role played by the interaction of plasma proteins, including complement, with reperfused endothelium remains incompletely understood. Venular endothelial changes due to hypoxia followed by reoxygenation (H-R) are vital because venules are th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of surgical research 1998-07, Vol.77 (2), p.91-98
Hauptverfasser: Gupta, N., Jacobs, D.L., Miller, T.A., Smith, G.S., Dahms, T.E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 98
container_issue 2
container_start_page 91
container_title The Journal of surgical research
container_volume 77
creator Gupta, N.
Jacobs, D.L.
Miller, T.A.
Smith, G.S.
Dahms, T.E.
description The pathophysiology of ischemia–reperfusion injury and the role played by the interaction of plasma proteins, including complement, with reperfused endothelium remains incompletely understood. Venular endothelial changes due to hypoxia followed by reoxygenation (H-R) are vital because venules are the primary site of fluid accumulation and polymorphonuclear leukocyte deposition due to inflammation. This investigation focused on whether H-R potentiates the response to permeability inducing agents found in activated plasma. Activated complement was studied by using zymosan activated plasma (ZAP). Permeability changes were assessed by quantitating rate of clearance of albumin across the monolayers. H-R alone did not change permeability relative to the normoxic condition. ZAP at 2% in normoxic cells increased albumin clearance from 2 ± 0.2 to 9 ± 1.0 μL/h, which increased significantly to 13.5 ± 2.0 μL/h when given to hypoxia–reoxygenation challenged monolayers. The permeability response to ZAP was dose related and not present with heat inactivated ZAP. ZAP at 2% altered the structure of the cytoskeleton of the human umbilical vein endothelial cells (HUVEC). However, addition of monoclonal anti-complement antibodies or addition of soluble complement receptor-1 did not attenuate ZAP-induced HUVEC permeability. Addition of zymosan-activated serum did not alter the permeability and addition of heparin inhibited the ZAP-induced changes in permeability, suggesting that these changes were mediated via thrombin and not complement. The increase in monolayer permeability due to ZAP was prevented by increasing intracellular adenosine-3′,5′-cyclic monophosphate. These findings suggest that HUVEC monolayers challenged with H-R are more susceptible to increases in permeability induced by activated plasma components.
doi_str_mv 10.1006/jsre.1998.5344
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73906204</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022480498953446</els_id><sourcerecordid>73906204</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-2921e60e8555a58cfecca70616d3f1dc888179536469ce892bd280ae11c6b7a13</originalsourceid><addsrcrecordid>eNp1kM2KFDEQgIMo6-zq1ZvQB_HWY36608lxWVZ3YMFFFMFLqElXa4buZEzSy_bNd_AN90nMMMPevFRRVV8VxUfIG0bXjFL5YZcirpnWat2KpnlGVozqtlayE8_JilLO60bR5iU5T2lHS607cUbOShStFivy_WbZhwcHj3_-fsHwsPxED9kFX92FjD47yJiqH8sUEvjq0mZ3Xzp9dTdCmqDe-H62pbz2fci_cHQwVhu_m-PyirwYYEz4-pQvyLeP11-vburbz582V5e3tRVS5ZprzlBSVG3bQqvsgNZCRyWTvRhYb5VSrNOtkI3UFpXm254rCsiYldsOmLgg74939zH8njFlM7lkcRzBY5iT6YSmktOmgOsjaGNIxdlg9tFNEBfDqDmYNAeT5mDSHEyWhbeny_N2wv4JP6kr83enOSQL4xDBW5eeMC4UZ0IWTB0xLBbuHUaTrENfrLmINps-uP998A-oA5Ed</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73906204</pqid></control><display><type>article</type><title>Hypoxia–Reoxygenation Potentiates Zymosan Activated Plasma-Induced Endothelial Injury</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Gupta, N. ; Jacobs, D.L. ; Miller, T.A. ; Smith, G.S. ; Dahms, T.E.</creator><creatorcontrib>Gupta, N. ; Jacobs, D.L. ; Miller, T.A. ; Smith, G.S. ; Dahms, T.E.</creatorcontrib><description>The pathophysiology of ischemia–reperfusion injury and the role played by the interaction of plasma proteins, including complement, with reperfused endothelium remains incompletely understood. Venular endothelial changes due to hypoxia followed by reoxygenation (H-R) are vital because venules are the primary site of fluid accumulation and polymorphonuclear leukocyte deposition due to inflammation. This investigation focused on whether H-R potentiates the response to permeability inducing agents found in activated plasma. Activated complement was studied by using zymosan activated plasma (ZAP). Permeability changes were assessed by quantitating rate of clearance of albumin across the monolayers. H-R alone did not change permeability relative to the normoxic condition. ZAP at 2% in normoxic cells increased albumin clearance from 2 ± 0.2 to 9 ± 1.0 μL/h, which increased significantly to 13.5 ± 2.0 μL/h when given to hypoxia–reoxygenation challenged monolayers. The permeability response to ZAP was dose related and not present with heat inactivated ZAP. ZAP at 2% altered the structure of the cytoskeleton of the human umbilical vein endothelial cells (HUVEC). However, addition of monoclonal anti-complement antibodies or addition of soluble complement receptor-1 did not attenuate ZAP-induced HUVEC permeability. Addition of zymosan-activated serum did not alter the permeability and addition of heparin inhibited the ZAP-induced changes in permeability, suggesting that these changes were mediated via thrombin and not complement. The increase in monolayer permeability due to ZAP was prevented by increasing intracellular adenosine-3′,5′-cyclic monophosphate. These findings suggest that HUVEC monolayers challenged with H-R are more susceptible to increases in permeability induced by activated plasma components.</description><identifier>ISSN: 0022-4804</identifier><identifier>EISSN: 1095-8673</identifier><identifier>DOI: 10.1006/jsre.1998.5344</identifier><identifier>PMID: 9733593</identifier><identifier>CODEN: JSGRA2</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Actins - metabolism ; Antibodies, Monoclonal - pharmacology ; Anticoagulants - pharmacology ; Biological and medical sciences ; Blood Proteins - pharmacology ; Blood Proteins - physiology ; Bucladesine - pharmacology ; Cardiovascular system ; Cells, Cultured ; Colforsin - pharmacology ; Complement System Proteins - physiology ; Cyclic AMP - metabolism ; Cytoskeleton - drug effects ; Cytoskeleton - metabolism ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - metabolism ; Hemostatics - pharmacology ; Heparin - pharmacology ; Humans ; Hypoxia - metabolism ; Medical sciences ; Oxygen - pharmacology ; Pharmacology. Drug treatments ; Receptors, Complement ; Solubility ; Thrombin - pharmacology ; Umbilical Veins - cytology ; Vascular wall ; Zymosan - pharmacology</subject><ispartof>The Journal of surgical research, 1998-07, Vol.77 (2), p.91-98</ispartof><rights>1998 Academic Press</rights><rights>1998 INIST-CNRS</rights><rights>Copyright 1998 Academic Press.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-2921e60e8555a58cfecca70616d3f1dc888179536469ce892bd280ae11c6b7a13</citedby><cites>FETCH-LOGICAL-c368t-2921e60e8555a58cfecca70616d3f1dc888179536469ce892bd280ae11c6b7a13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1006/jsre.1998.5344$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2382136$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9733593$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gupta, N.</creatorcontrib><creatorcontrib>Jacobs, D.L.</creatorcontrib><creatorcontrib>Miller, T.A.</creatorcontrib><creatorcontrib>Smith, G.S.</creatorcontrib><creatorcontrib>Dahms, T.E.</creatorcontrib><title>Hypoxia–Reoxygenation Potentiates Zymosan Activated Plasma-Induced Endothelial Injury</title><title>The Journal of surgical research</title><addtitle>J Surg Res</addtitle><description>The pathophysiology of ischemia–reperfusion injury and the role played by the interaction of plasma proteins, including complement, with reperfused endothelium remains incompletely understood. Venular endothelial changes due to hypoxia followed by reoxygenation (H-R) are vital because venules are the primary site of fluid accumulation and polymorphonuclear leukocyte deposition due to inflammation. This investigation focused on whether H-R potentiates the response to permeability inducing agents found in activated plasma. Activated complement was studied by using zymosan activated plasma (ZAP). Permeability changes were assessed by quantitating rate of clearance of albumin across the monolayers. H-R alone did not change permeability relative to the normoxic condition. ZAP at 2% in normoxic cells increased albumin clearance from 2 ± 0.2 to 9 ± 1.0 μL/h, which increased significantly to 13.5 ± 2.0 μL/h when given to hypoxia–reoxygenation challenged monolayers. The permeability response to ZAP was dose related and not present with heat inactivated ZAP. ZAP at 2% altered the structure of the cytoskeleton of the human umbilical vein endothelial cells (HUVEC). However, addition of monoclonal anti-complement antibodies or addition of soluble complement receptor-1 did not attenuate ZAP-induced HUVEC permeability. Addition of zymosan-activated serum did not alter the permeability and addition of heparin inhibited the ZAP-induced changes in permeability, suggesting that these changes were mediated via thrombin and not complement. The increase in monolayer permeability due to ZAP was prevented by increasing intracellular adenosine-3′,5′-cyclic monophosphate. These findings suggest that HUVEC monolayers challenged with H-R are more susceptible to increases in permeability induced by activated plasma components.</description><subject>Actins - metabolism</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Anticoagulants - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Blood Proteins - pharmacology</subject><subject>Blood Proteins - physiology</subject><subject>Bucladesine - pharmacology</subject><subject>Cardiovascular system</subject><subject>Cells, Cultured</subject><subject>Colforsin - pharmacology</subject><subject>Complement System Proteins - physiology</subject><subject>Cyclic AMP - metabolism</subject><subject>Cytoskeleton - drug effects</subject><subject>Cytoskeleton - metabolism</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - metabolism</subject><subject>Hemostatics - pharmacology</subject><subject>Heparin - pharmacology</subject><subject>Humans</subject><subject>Hypoxia - metabolism</subject><subject>Medical sciences</subject><subject>Oxygen - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, Complement</subject><subject>Solubility</subject><subject>Thrombin - pharmacology</subject><subject>Umbilical Veins - cytology</subject><subject>Vascular wall</subject><subject>Zymosan - pharmacology</subject><issn>0022-4804</issn><issn>1095-8673</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM2KFDEQgIMo6-zq1ZvQB_HWY36608lxWVZ3YMFFFMFLqElXa4buZEzSy_bNd_AN90nMMMPevFRRVV8VxUfIG0bXjFL5YZcirpnWat2KpnlGVozqtlayE8_JilLO60bR5iU5T2lHS607cUbOShStFivy_WbZhwcHj3_-fsHwsPxED9kFX92FjD47yJiqH8sUEvjq0mZ3Xzp9dTdCmqDe-H62pbz2fci_cHQwVhu_m-PyirwYYEz4-pQvyLeP11-vburbz582V5e3tRVS5ZprzlBSVG3bQqvsgNZCRyWTvRhYb5VSrNOtkI3UFpXm254rCsiYldsOmLgg74939zH8njFlM7lkcRzBY5iT6YSmktOmgOsjaGNIxdlg9tFNEBfDqDmYNAeT5mDSHEyWhbeny_N2wv4JP6kr83enOSQL4xDBW5eeMC4UZ0IWTB0xLBbuHUaTrENfrLmINps-uP998A-oA5Ed</recordid><startdate>19980701</startdate><enddate>19980701</enddate><creator>Gupta, N.</creator><creator>Jacobs, D.L.</creator><creator>Miller, T.A.</creator><creator>Smith, G.S.</creator><creator>Dahms, T.E.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980701</creationdate><title>Hypoxia–Reoxygenation Potentiates Zymosan Activated Plasma-Induced Endothelial Injury</title><author>Gupta, N. ; Jacobs, D.L. ; Miller, T.A. ; Smith, G.S. ; Dahms, T.E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-2921e60e8555a58cfecca70616d3f1dc888179536469ce892bd280ae11c6b7a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Actins - metabolism</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Anticoagulants - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Blood Proteins - pharmacology</topic><topic>Blood Proteins - physiology</topic><topic>Bucladesine - pharmacology</topic><topic>Cardiovascular system</topic><topic>Cells, Cultured</topic><topic>Colforsin - pharmacology</topic><topic>Complement System Proteins - physiology</topic><topic>Cyclic AMP - metabolism</topic><topic>Cytoskeleton - drug effects</topic><topic>Cytoskeleton - metabolism</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - metabolism</topic><topic>Hemostatics - pharmacology</topic><topic>Heparin - pharmacology</topic><topic>Humans</topic><topic>Hypoxia - metabolism</topic><topic>Medical sciences</topic><topic>Oxygen - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, Complement</topic><topic>Solubility</topic><topic>Thrombin - pharmacology</topic><topic>Umbilical Veins - cytology</topic><topic>Vascular wall</topic><topic>Zymosan - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gupta, N.</creatorcontrib><creatorcontrib>Jacobs, D.L.</creatorcontrib><creatorcontrib>Miller, T.A.</creatorcontrib><creatorcontrib>Smith, G.S.</creatorcontrib><creatorcontrib>Dahms, T.E.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of surgical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gupta, N.</au><au>Jacobs, D.L.</au><au>Miller, T.A.</au><au>Smith, G.S.</au><au>Dahms, T.E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypoxia–Reoxygenation Potentiates Zymosan Activated Plasma-Induced Endothelial Injury</atitle><jtitle>The Journal of surgical research</jtitle><addtitle>J Surg Res</addtitle><date>1998-07-01</date><risdate>1998</risdate><volume>77</volume><issue>2</issue><spage>91</spage><epage>98</epage><pages>91-98</pages><issn>0022-4804</issn><eissn>1095-8673</eissn><coden>JSGRA2</coden><abstract>The pathophysiology of ischemia–reperfusion injury and the role played by the interaction of plasma proteins, including complement, with reperfused endothelium remains incompletely understood. Venular endothelial changes due to hypoxia followed by reoxygenation (H-R) are vital because venules are the primary site of fluid accumulation and polymorphonuclear leukocyte deposition due to inflammation. This investigation focused on whether H-R potentiates the response to permeability inducing agents found in activated plasma. Activated complement was studied by using zymosan activated plasma (ZAP). Permeability changes were assessed by quantitating rate of clearance of albumin across the monolayers. H-R alone did not change permeability relative to the normoxic condition. ZAP at 2% in normoxic cells increased albumin clearance from 2 ± 0.2 to 9 ± 1.0 μL/h, which increased significantly to 13.5 ± 2.0 μL/h when given to hypoxia–reoxygenation challenged monolayers. The permeability response to ZAP was dose related and not present with heat inactivated ZAP. ZAP at 2% altered the structure of the cytoskeleton of the human umbilical vein endothelial cells (HUVEC). However, addition of monoclonal anti-complement antibodies or addition of soluble complement receptor-1 did not attenuate ZAP-induced HUVEC permeability. Addition of zymosan-activated serum did not alter the permeability and addition of heparin inhibited the ZAP-induced changes in permeability, suggesting that these changes were mediated via thrombin and not complement. The increase in monolayer permeability due to ZAP was prevented by increasing intracellular adenosine-3′,5′-cyclic monophosphate. These findings suggest that HUVEC monolayers challenged with H-R are more susceptible to increases in permeability induced by activated plasma components.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>9733593</pmid><doi>10.1006/jsre.1998.5344</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-4804
ispartof The Journal of surgical research, 1998-07, Vol.77 (2), p.91-98
issn 0022-4804
1095-8673
language eng
recordid cdi_proquest_miscellaneous_73906204
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Actins - metabolism
Antibodies, Monoclonal - pharmacology
Anticoagulants - pharmacology
Biological and medical sciences
Blood Proteins - pharmacology
Blood Proteins - physiology
Bucladesine - pharmacology
Cardiovascular system
Cells, Cultured
Colforsin - pharmacology
Complement System Proteins - physiology
Cyclic AMP - metabolism
Cytoskeleton - drug effects
Cytoskeleton - metabolism
Endothelium, Vascular - drug effects
Endothelium, Vascular - metabolism
Hemostatics - pharmacology
Heparin - pharmacology
Humans
Hypoxia - metabolism
Medical sciences
Oxygen - pharmacology
Pharmacology. Drug treatments
Receptors, Complement
Solubility
Thrombin - pharmacology
Umbilical Veins - cytology
Vascular wall
Zymosan - pharmacology
title Hypoxia–Reoxygenation Potentiates Zymosan Activated Plasma-Induced Endothelial Injury
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T14%3A40%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypoxia%E2%80%93Reoxygenation%20Potentiates%20Zymosan%20Activated%20Plasma-Induced%20Endothelial%20Injury&rft.jtitle=The%20Journal%20of%20surgical%20research&rft.au=Gupta,%20N.&rft.date=1998-07-01&rft.volume=77&rft.issue=2&rft.spage=91&rft.epage=98&rft.pages=91-98&rft.issn=0022-4804&rft.eissn=1095-8673&rft.coden=JSGRA2&rft_id=info:doi/10.1006/jsre.1998.5344&rft_dat=%3Cproquest_cross%3E73906204%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73906204&rft_id=info:pmid/9733593&rft_els_id=S0022480498953446&rfr_iscdi=true